Repurposing of Compounds from Streptomyces spp. as Potential Inhibitors of Aminoacyltransferase FemA : An Essential Drug Target against Drug-resistant Staphylococcus aureus
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Drug-resistant Staphylococcus aureus represents a substantial healthcare challenge worldwide, and its range of available therapeutic options continues to diminish progressively. Thus, this study aimed to identify potential inhibitors against FemA, a crucial protein involved in the cell wall biosynthesis of S. aureus.
MATERIALS AND METHODS: The screening process involved a comprehensive structure-based virtual screening on the StreptomDB database to identify ligands with potential inhibitory effects on FemA using AutoDock Vina. The most desirable ligands with the highest binding affinity and pharmacokinetic properties were selected. Two ligands with the highest number of hydrogen bonds and hydrophobic interactions were further analyzed by molecular dynamics (MD) using the GROMACS version 2018 simulation package.
RESULTS: Six H-donor conserved residues were selected as protein active sites, including Arg- 220, Tyr-38, Gln-154, Asn-73, Arg-74, and Thr-24. Through virtual screening, a total of nine compounds with the highest binding affinity to the FemA protein were identified. Frigocyclinone and C21H21N3O4 exhibited the highest binding affinity and demonstrated favorable pharmacokinetic properties. Molecular dynamics analysis of the FemA-ligand complexes further indicated desirable stability and reliability of complexes, reinforcing the potential efficacy of these ligands as inhibitors of FemA protein.
CONCLUSION: Our findings suggest that Frigocyclinone and C21H21N3O4 are promising inhibitors of FemA in S. aureus. To further validate these computational results, experimental studies are planned to confirm the inhibitory effects of these compounds on various S. aureus strains. Combining computational screening with experimental validation contributes valuable insights to the field of drug discovery in comparison to the classical drug discovery approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current computer-aided drug design - (2024) vom: 20. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goodarzi, Narjes Noori [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug discovery |
|---|
| Anmerkungen: |
Date Revised 25.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115734099297360240312043642 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370131118 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370131118 | ||
| 003 | DE-627 | ||
| 005 | 20240325235837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115734099297360240312043642 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1347.xml |
| 035 | |a (DE-627)NLM370131118 | ||
| 035 | |a (NLM)38523540 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goodarzi, Narjes Noori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing of Compounds from Streptomyces spp. as Potential Inhibitors of Aminoacyltransferase FemA |b An Essential Drug Target against Drug-resistant Staphylococcus aureus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Drug-resistant Staphylococcus aureus represents a substantial healthcare challenge worldwide, and its range of available therapeutic options continues to diminish progressively. Thus, this study aimed to identify potential inhibitors against FemA, a crucial protein involved in the cell wall biosynthesis of S. aureus | ||
| 520 | |a MATERIALS AND METHODS: The screening process involved a comprehensive structure-based virtual screening on the StreptomDB database to identify ligands with potential inhibitory effects on FemA using AutoDock Vina. The most desirable ligands with the highest binding affinity and pharmacokinetic properties were selected. Two ligands with the highest number of hydrogen bonds and hydrophobic interactions were further analyzed by molecular dynamics (MD) using the GROMACS version 2018 simulation package | ||
| 520 | |a RESULTS: Six H-donor conserved residues were selected as protein active sites, including Arg- 220, Tyr-38, Gln-154, Asn-73, Arg-74, and Thr-24. Through virtual screening, a total of nine compounds with the highest binding affinity to the FemA protein were identified. Frigocyclinone and C21H21N3O4 exhibited the highest binding affinity and demonstrated favorable pharmacokinetic properties. Molecular dynamics analysis of the FemA-ligand complexes further indicated desirable stability and reliability of complexes, reinforcing the potential efficacy of these ligands as inhibitors of FemA protein | ||
| 520 | |a CONCLUSION: Our findings suggest that Frigocyclinone and C21H21N3O4 are promising inhibitors of FemA in S. aureus. To further validate these computational results, experimental studies are planned to confirm the inhibitory effects of these compounds on various S. aureus strains. Combining computational screening with experimental validation contributes valuable insights to the field of drug discovery in comparison to the classical drug discovery approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FemA | |
| 650 | 4 | |a Staphylococcus aureus | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a drug repurposing. | |
| 650 | 4 | |a molecular dynamics | |
| 650 | 4 | |a structure-based virtual screening | |
| 700 | 1 | |a Shahbazi, Behzad |e verfasserin |4 aut | |
| 700 | 1 | |a Khiavi, Elham Haj Agha Gholizadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Asforooshani, Mahshid Khazani |e verfasserin |4 aut | |
| 700 | 1 | |a Abed, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Badmasti, Farzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current computer-aided drug design |d 2008 |g (2024) vom: 20. März |w (DE-627)NLM191691046 |x 1875-6697 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115734099297360240312043642 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 03 | ||